Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $5.9 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 8.0% year-over-year to $5.9 billion; the TTM figure through Mar 2026 stood at $5.9 billion (up 8.0% YoY), while the FY2025 annual figure was $5.7 billion, up 11.72% from the prior year.
• Total Non-Current Liabilities was $5.9 billion for Q1 2026 at Vertex Pharmaceuticals, up from $5.7 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $6.3 billion in Q3 2025 to a low of $3.2 billion in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $4.7 billion across 5 years, with a median of $4.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities grew 7.49% in 2022, then jumped 30.66% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $3.6 billion in 2022, then climbed by 20.26% to $4.3 billion in 2023, then climbed by 19.59% to $5.1 billion in 2024, then advanced by 11.72% to $5.7 billion in 2025, then climbed by 2.79% to $5.9 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $5.9 billion (Q1 2026), $5.7 billion (Q4 2025), and $6.3 billion (Q3 2025), per Business Quant data.